



Claims

1. A pharmaceutically acceptable salt of a compound of formula (I):




or an enantiomer thereof, wherein the salt is a malonate salt.

2. The salt according to claim 1, wherein the compound is formula (IA) is:




(IA).

3. The salt according to any one of claims 1 or 2, wherein the purity of the salt is 97% or greater, such as 97.5%, 98%, 98.5%, 99% or 99.5%, for example when analysed by HPLC or similar techniques and expressed as an area/area value (%area).
4. The salt according to any one of claims 1 to 3, wherein salt contains 0.1 % or less of an aniline impurity $C_{18}H_{14}ClN_5OS$, for example when analysed by HPLC or similar techniques and expressed as an area/area value.
5. The salt according to claim 4, wherein the aniline impurity has the structure of formula (II):



(II).

6. The salt according to claims 4 or 5, wherein said aniline impurity is present at 0.09% or less, for example 0.08%, 0.06%, 0.05 or less.
7. The salt according to any one of claims 1 to 6, wherein the salt contains 1.5% or less, for example 1.5%, 1.4%, 1.3%, 1.2%, 1.1%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5% or less of a thiazoline impurity $C_{22}H_{19}ClN_6OS_2$, for example when analysed by HPLC or similar techniques and expressed as an area/area value (%area).
8. The salt according to claim 7, wherein thiazoline impurity has the structure of formula (III):



(III).

9. A pharmaceutical composition comprising a salt according to any one of claims 1 to 8.
10. A pharmaceutical composition according to claim 9, wherein the composition is for oral administration.
11. A pharmaceutical composition according to claim 9 or 10, wherein the dose of free base equivalent provided by the malonate salt is in the range 100mg to 900mg, such as 200mg to 500mg, in particular 200mg, 300mg, or 400mg.
12. A salt according to any one of claims 1 to 8 or a pharmaceutical composition according to any one of claims 9 to 11 for use in treatment.
13. Use of a salt according to any one of claims 1 to 8 or a composition according to any one of claims 9 to 11, for the manufacture of a medicament for the treatment of cancer.
14. A salt, composition, or use according to any one of claims 12 to 13 wherein the salt of formula (I) is administered bi-daily.
15. A salt, composition, or use according to any one of claims 12 to 14, wherein the therapy comprises a further therapeutic agent, for example herein the further therapeutic agent is an anticancer agent.
16. A salt, composition, or use according to claim 15, wherein the further therapeutic agent is a chemotherapeutic agent or combination thereof.
17. A salt, composition, or use according to claim 16, wherein the chemotherapeutic agent is selected from the group comprising a platinum based chemotherapeutic, a pyrimidine analogue and combinations of two or more the same.
18. A salt, composition, or use according to claim 17, wherein the platinum based chemotherapeutic agent is selected from the group comprising cisplatin, carboplatin, oxaliplatin, satraplatin, picoplatin, nedaplatin, triplatin, lipoplatin and combinations thereof, in particular cisplatin.
19. A salt, composition, or use according to claim 16 or 17 wherein the chemotherapeutic agent is selected from fluorouracil (5-FU), capecitabine, gemcitabine, Raltitrexed, taxol and derivatives thereof, BGC 945, OSI-7904L, FOLFOX, FOLFIRI and FOLFIRINOX, and combinations of two or more of the same.